Many clinical trials have been conducted to show the clinical benefit of various types of tumors from anti-PD-1/PD-L1 immunotherapy, such as malignant melanoma, non-small cell lung cancer, and renal cell carcinoma [27, 28]. This evidence concerns the gene CD274 and renal cell carcinoma.